Previous 10 | Next 10 |
HINGHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a network of global leaders in the endovascular interventional space for the LIBERTY® Robotic System, today announced that Vincent Vidal, M.D., PhD, has joined its Scientif...
HINGHAM, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, Chairman, President and CEO, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference being held in NYC. Mr. Gadot will provide an overview of the C...
HINGHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announces the commencement of its GLP Pre-Clinical Trial for the LIBERTY Robotic System at a world-class MedTech research laboratory. The study is being conducted by top Key Opinion Leaders (KOLs). ...
A global leader in the endovascular space will collaborate with the Company as it goes through the regulatory process and future commercialization HINGHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a reputation within ...
HINGHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Demonstrating another key achievement, Microbot Medical Inc. (Nasdaq: MBOT), continues to execute its objective of expanding its global intellectual property (IP) portfolio for the LIBERTY ® Robotic System as a grant for two Design...
Microbot Medical ( NASDAQ: MBOT ) is trading 5.5% higher after the company said it shipped multiple Liberty Robotic System devices to a market-leading research laboratory to conduct the Company’s GLP pre-clinical trial. The comprehensive trial, which is anticipa...
HINGHAM, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced, as part of the preparation for its anticipated U.S. Food and Drug Administration (FDA) and CE Mark submissions, that it recently shipped multiple LIBERTY Robotic System devices to a market-lea...
HINGHAM, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company’s Self-Cleaning Shunt (SCS) at the 16 th Asian Australasian Congress of Neurological Surgeons (AACNS). The AACNS is hosted by the Israel N...
HINGHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced it will be presenting at the Annual Needham Virtual Healthcare Conference. Harel Gadot, Chairman, President and CEO will provide an overview of the Company and recent progress on Tuesday, Apri...
Microbot Medical (NASDAQ:MBOT) has promoted Rachel Vaknin as its Chief Financial Officer (CFO), effective Apr. 1, 2022. Ms. Vaknin is a seasoned finance executive with 20 years of experience. She joined Microbot in Jan'22 as VP Finance and succeeds David Ben Naim as CFO. Ben Naim had served a...
News, Short Squeeze, Breakout and More Instantly...
Microbot Medical Inc. Company Name:
MBOT Stock Symbol:
NASDAQ Market:
Microbot Medical Inc. Website:
BRAINTREE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces it has received Institutional Review Board (IRB) approval and signed a clinical trial agreement with Memor...
Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical Trial. The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular R...
The first clinical case was performed at Brigham and Women’s Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY ® Endovascular Robotic Surgical System BRAINTREE, Mass., July 08, 2024 (G...